Almirall, S.A.

MCE ALM.MC

Almirall, S.A. Price to Earnings Ratio (P/E) on January 14, 2025: -43.14

Almirall, S.A. Price to Earnings Ratio (P/E) is -43.14 on January 14, 2025, a 8.66% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Almirall, S.A. 52-week high Price to Earnings Ratio (P/E) is -39.54 on December 06, 2024, which is 8.34% above the current Price to Earnings Ratio (P/E).
  • Almirall, S.A. 52-week low Price to Earnings Ratio (P/E) is -53.51 on June 17, 2024, which is -24.04% below the current Price to Earnings Ratio (P/E).
  • Almirall, S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is -47.68.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
MCE: ALM.MC

Almirall, S.A.

CEO Mr. Carlos Gallardo Piqué
IPO Date June 20, 2007
Location Spain
Headquarters Ronda Del General Miter, 151
Employees 1,904
Sector Health Care
Industries
Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Similar companies

ACX.MC

Acerinox, S.A.

USD 9.88

0.19%

ROVI.MC

Laboratorios Farmaceuticos Rovi, S.A.

USD 59.78

-0.59%

CIE.MC

CIE Automotive, S.A.

USD 25.46

1.01%

GRF.MC

Grifols, S.A.

USD 9.29

3.24%

ENC.MC

ENCE Energía y Celulosa, S.A.

USD 3.25

1.25%

StockViz Staff

January 15, 2025

Any question? Send us an email